Recurrent genetic defects on chromosome 7q in myeloid neoplasms
暂无分享,去创建一个
S. Miyano | Y. Shiraishi | K. Chiba | S. Ogawa | M. McDevitt | A. Verma | J. Maciejewski | Kenichi Yoshida | M. Sanada | A. Jerez | M. Sekeres | H. Makishima | N. Hosono | B. Przychodzen | K. Yoshida | S. McMahon | H. Tanaka | I. Gómez-Seguí | A. Verma | S. Mcmahon | Sarah Mcmahon | Hirokazu Tanaka | Amit Verma
[1] S. Vincent Rajkumar,et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.
[2] S. Miyano,et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies , 2013, Leukemia.
[3] A. Jankowska,et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies , 2013, Leukemia.
[4] A. Lane,et al. Putative RNA-splicing gene LUC7L2 on 7q34 represents a candidate gene in pathogenesis of myeloid malignancies , 2013, Blood Cancer Journal.
[5] M. Kaminski,et al. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. , 2012, Blood.
[6] A. Jankowska,et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. , 2012, Blood.
[7] Laura Hulea,et al. CUX1 transcription factors: from biochemical activities and cell-based assays to mouse models and human diseases. , 2012, Gene.
[8] S. Ogawa,et al. Novel CUX1 missense mutation in association with 7q− at leukemic transformation of MPN , 2011, American journal of hematology.
[9] P. Sonneveld,et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. , 2011, Blood.
[10] K. McGlynn,et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. , 2010, Blood.
[11] A. Jankowska,et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies , 2010, Leukemia.
[12] H. Drexler,et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.
[13] R. Kuiper,et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.
[14] I. Turesson,et al. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] M. Gordon. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .
[16] D. Dingli,et al. Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.
[17] H. Brenner,et al. Recent major improvement in long-term survival of younger patients with multiple myeloma. , 2008, Blood.
[18] M. Meisler,et al. Evidence for a direct role of the disease modifier SCNM1 in splicing. , 2007, Human molecular genetics.
[19] P. Dickman,et al. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B. Bedell,et al. Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia. , 2006, Cancer research.
[21] A. Nepveu,et al. Role of the multifunctional CDP/Cut/Cux homeodomain transcription factor in regulating differentiation, cell growth and development. , 2001, Gene.
[22] M. Poo,et al. Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates , 1999, Cell.
[23] M. Scheffner,et al. Interaction between ubiquitin–protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation , 1999, Nature Cell Biology.
[24] Edward T Kipreos,et al. cul-1 Is Required for Cell Cycle Exit in C. elegans and Identifies a Novel Gene Family , 1996, Cell.